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Abstract: The synthetic material Nanobone® (hydroxyapatite nanocrystallines embedded in a 
porous silica gel matrix) was examined in vivo using a standardized bone defect model in the 
ovine tibial metaphysis. A standardized 6 × 12 × 24-mm bone defect was created below the 
articular surface of the medial tibia condyles on both hind legs of 18 adult sheep. The defect 
on the right side was filled with Nanobone®, while the defect on the contralateral side was left 
empty. The tibial heads of six sheep were analyzed after 6, 12, and 26 weeks each. The histologi-
cal and radiological analysis of the defect on the control side did not reveal any bone formation 
after the total of 26 weeks. In contrast, the microcomputed tomography analysis of the defect 
filled with Nanobone® showed a 55%, 72%, and 74% volume fraction of structures with bone 
density after 6, 12, and 26 weeks, respectively. Quantitative histomorphological analysis after 6, 
and 12 weeks revealed an osteoneogenesis of 22%, and 36%, respectively. Hematoxylin and 
eosin sections demonstrated multinucleated giant cells on the surface of the biomaterial and 
resorption lacunae, indicating osteoclastic resorptive activity. Nanobone® appears to be a highly 
potent bone substitute material with osteoconductive properties in a loaded large animal defect 
model, supporting the potential use of Nanobone® also in humans.
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Introduction
The treatment of defects in large bones is a challenge for orthopedic surgeons. Bone 
transplants or bone substitutes are necessary in about 10% of all reconstructive 
procedures due to trauma or to fill resectional voids as well as to correct congenital 
defects. Autologous bone grafting continues to be the “gold standard” for defect filling 
in reconstructive surgery. Nevertheless, major problems still exist with autologous bone 
grafting. These include donor site morbidity with residual complications in up to 50% 
of the procedures and the limited availability of autologous bone itself.1 Allografts 
have been used extensively but these raise concerns of potential contamination and 
mechanical stability. Sensitive blood tests, donor screening, and extensive efforts 
to clean bone and clear it of infectious agents have helped to alleviate the concern 
regarding contamination. Fatigue fractures are a common problem when using cortical 
allografts. Many of the failures of these bone grafts are due to mechanical problems 
that are related to the biologic incorporation of the graft. Inorganic implants, such as 
synthetic calcium-phosphate-based bone substitutes, seem to be useful alternatives to 
autologous bone grafting.2 Hydroxyapatite (HA) is the main inorganic bone matrix 
component. Synthetic HA, when used as a bone graft, has shown a high degree of 
biocompatibility and support for cellular activity. It stimulates osteoconduction 
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and is generally slowly replaced by the host bone after 
implantation.3 Since the 1980s, blocks and granules of porous 
synthetic HA have been used in orthopedic, craniofacial, and 
dental applications.4 Continuous improvements in synthesis, 
manufacturing technology, and purification have led to a 
variety of synthetic HA materials and forms with different 
properties.1,5
Broadly termed “bioceramics,” these forms of synthetic 
HA and beta-tricalciumphosphate (βTCP) are increasingly 
being used as bone substitutes for grafting into defects or 
as coatings on permanent implants. The bone graft sub-
stitute Nanobone® used in this study is a nanocrystalline 
hydroxyapatite embedded in a porous silica gel matrix. 
Unlike   conventional HA forms that are usually sintered at 
temperatures ranging from 700°C up to 1200°C, Nanobone® 
is produced at a temperature , 200°C.6 The lower processing 
temperature has a profound effect on the material’s porosity 
and surface area. For example, a large surface area enhances 
the solubility, tissue reaction, and osteoclastic activity.
Nanobone® has been shown to have in vivo osteocon-
ductive properties on dermal bone.7 The material has been 
tested in jaws of mini-pigs and has recently been used 
successfully to fill dentoalveolar defects in man.8–10 This 
early clinical experience with the material in mandibular 
reconstructive surgery has been encouraging. However, 
there is no experimental or clinical experience with the use 
of Nanobone in a weight-bearing long-bone model. The aim 
of this investigation was to assess the biodegradation and the 
osteogenic potential of this nanocrystalline HA-based bone 
grafting material in a standardized weight-bearing defect in 
sheep. The sheep model is often used in biomaterial testing 
due to a higher similarity of the sheep’s bone metabolism 
to the human situation as compared to the bone metabolism 
of small animals.
Methods
The bone replacement material Nanobone® (Artoss,   Rostock, 
Germany) used in this study is a synthetic HA scaffold 
produced in a sol-gel process at temperatures of ,200°C.6 
The material consists of nanocrystalline HA embedded in a 
silica gel matrix. Solvent evaporation leads to the formation 
of small pores (∅ 5–100 µm) in the structure. After solvent 
evaporation the HA crystallites are loosely packed and held 
together by silica (SiO2). Because of the interconnecting 
pores the specific surface area of the material is high on the 
order of 84 m2/g. The volume fraction of the granules is about 
61%. The granules have a density of 0.4–0.7 g/cm3 and a 
typical compressive strength on the order of 40 MPa.11
Low temperature processing of the material offers several 
advantages.12 The rough surface structure of the granular 
material is a result of the material’s interconnecting porous 
structure. The porous structure and optimum pore size allow 
and promote bone ingrowth. Histological and immunohis-
tochemical studies demonstrated its osteoconductive nature 
and early remodeling in the host tissue.10,13,14 Animal experi-
ments, using a mini-pig critical-size defect model in alveolar 
bone, showed high rates of bone formation and nearly com-
plete resorption of the implant within 8 months.15
Animal model
The study protocol of this investigation followed national 
guidelines and regulations for the care and use of labora-
tory animals and was approved by the local authorities 
(Landesamt für Landwirtschaft, Lebensmittelsicherheit und 
Fischerei Mecklenburg-Vorpommern, Germany; LALLF 
M-V/TST/7221.3-1.1-019/06).
A well-established, weight-bearing, large animal model16–18 
was used for investigation of the graft material. Eighteen mature 
female Mecklenburg sheep with an average body weight of 
63 kg were operated on under general anesthesia induced by 
intravenous injection of propofol. The sheep were maintained 
with isoflurane in 100% oxygen. Continuous electrocardiogram 
and pulsoxymetry were used during the operation to moni-
tor the sheep. Novaminsulfon was given perioperatively for 
pain relief and was continued for 2 days after the procedure. 
Antibiotic prophylaxis consisted of amoxicillin administered 
intravenously as a single dose preoperatively. The sheep were 
placed in supine position and both legs were shaved and disin-
fected with povidone-iodine. A longitudinal incision 15 cm in 
length was made on the medial side of the knee to expose the 
proximal tibia. Under continuous cooling with saline, a wedge-
shaped bone defect of 6 × 12 × 24 mm was cut in the medial 
aspect of the left and right proximal tibia 3 mm beneath the 
articular surface, using a specially designed guiding fixture.16 
Bone debris was removed by lavage, and bleeding was stopped 
by tamponade. On the left side the defect was left empty. On 
the right side the defect was filled with the bone substitute, 
which had been mixed with 5 mL of venous blood according 
to the manufacturer’s instructions. The wound was closed in 
layers with absorbable sutures and covered with a dressing. 
Subsequently, the sheep were returned to their stable. Due to 
the integrity of the lateral condyles and the dense bone structure 
in sheep, no additional stabilization was needed. The animals 
were mobilized under full weight bearing of both hind legs.
At intervals of 6, 12, and 26 weeks after the intervention, 
six sheep, in deep anesthesia induced with pentobarbital, 
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were sacrificed at each time point with potassium   chloride. 
The operated tibiae were harvested and evaluated for 
periosteal integrity. Conventional radiographs and computed 
tomography (CT) scans were performed. The conventional 
CT scans were analyzed with a DICOM viewer (Osirix 3.5; 
Osirix Imaging Software, Geneva, Switzerland).
Micro-CT
After the specimens were harvested, a micro-CT was 
  performed on a bone block of 30 × 50 × 60 mm removed 
from the tibia. Six models with the same-sized defect as 
the in vivo defect were fabricated from a rigid plastic and 
filled with Nanobone® in the same manner as was done in 
the reference sheep.
Histological and histomorphometric 
evaluation
After fixation in formalin the harvested specimens were 
decalcified in neutral 10% ethylene diamine tetraacetic acid 
(EDTA) for 14 days, processed with graded concentrations of 
alcohol and embedded in paraffin. Decalcified sections were 
processed and stained with hematoxylin and eosin (HE) and 
Goldner–Masson trichrome to morphologically visualize the 
new bone formation and to distinguish between mature and 
immature bone. Enzyme and immunohistochemical analysis 
was performed with the respective markers as described 
previously.19,20 Enzyme histochemical staining against 
tartrate-resistant acid phosphatase (TRAP)   specifically stains 
osteoclasts and mononuclear precursor cells, indicating 
bone resorption during the remodeling process around and 
within the bone substitute. Osteocalcin as a noncollagenous 
matrix protein is expressed by osteoblasts and is   localized 
in the cement lines of newly formed bone trabeculae. 
Without background staining it is specifically seen in mature 
osteoblasts.
Semiquantitative histomorphometric analysis was per-
formed on micrographs from the HE-stained sections at 
1.25 × magnification using planimetric analysis (Axio Vision 
LE; Zeiss, Jena, Germany). The slices were scanned (Agfa 
Horizon Ultra®; Agfa, Köln, Germany) for documentation 
and for histomorphometric evaluation. The original images 
were prepared for histomorphometric analysis by editing 
with Adobe Photoshop® software (v. 6.0; Adobe, San Jose, 
CA). The implantation site where Nanobone® granules 
could be localized was defined as a region of interest (ROI). 
This area was digitally marked and measured using the 
AnaLYSIS® software (Soft Imaging System; GmbH,   Münster, 
  Germany). Within the ROI three fractions of tissue could 
be differentiated: newly formed bone, remnant bone graft 
substitute, and connective soft tissue. The areas with newly 
formed bone and with the remnant bone graft substitute were 
marked with different colors and the dimensions of these areas 
were determined. By subtracting these areas from the ROI, 
the area of soft tissue was calculated, and by relating these 
measured and calculated areas to the ROI, the percentage area 
for each could be established. The percentage of new bone 
that had been formed within the defect was calculated as well 
as the percentage of remaining bone graft material. The bone 
per tissue volume and the remaining graft material per tissue 
volume were determined, and the fraction of soft tissue was 
calculated. This process was repeated in three different sec-
tions of the same defect to ensure a representative sampling 
over the entire defect.
Statistical analysis
All data were expressed as means ± standard error of the 
mean. After testing for normality and equal variance across 
groups, difference points were assessed by two-way analysis 
of variance followed by an appropriate post-hoc comparison. 
For reasons of clarity and comprehensiveness, only statistical 
significant differences between the groups are shown in the 
figures. Statistical significance was set at P , 0.05.   Statistics 
were performed using the GraphPad Prism 5® software 
package (GraphPad Software, San Diego, CA).
Results
The animals returned to a normal walking pattern within 
7 days. No relevant complications necessitating surgical 
revision or sacrifice of the animals occurred throughout the 
experimental period.
The morphological investigation of the harvested tibiae 
showed an intact joint surface. The medial surface of the 
right and left tibiae was covered with a thick layer of scar 
tissue. Macroscopically, no sign of inflammation or adverse 
tissue reaction was seen.
Radiographic examination of the tibiae harvested from 
the left side (control) over the 26-week experimental period 
did not show spontaneous osseous ingrowth in any of the 
sheep. Conventional CT scanning confirmed the findings 
obtained by standard X-rays. Within the defect on the left 
side, no radiopaque tissue could be observed. By measuring 
the frontal CT reconstruction, the extent of the defect was 
shown to have remained constant at 6 mm. The control defect 
was filled with nonspecific fibrous tissue after 6, 12, and 
26 weeks as seen in Figure 1A. Histological analysis did not 
show any bone formation within the left tibia (Figure 1B). 
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The connective tissue that had formed within the defect was 
so loosely adherent that it was lost during sample preparation 
and could not be further evaluated histologically.
With histological and immunohistochemical analysis of 
the right tibiae, new bone formation and neovascularization 
were observed around the hydroxyapatite particles within 
the defect. Light microscopic evaluation revealed a consis-
tent bone response within each of the six specimens at each 
time period.
After 6 weeks multiple multinucleated giant cells and 
macrophages were seen at the interface of bone and the 
HA (Figure 1C). Judging from their enzyme histochemical 
activity against TRAP, these cells appear to be osteoclasts 
(Figure 1D).
An increase in the progression of new bone forma-
tion within the bone substitute material continued from 
6 to 12 weeks. Bone ingrowth occurred primarily from 
the margins of the defect toward the center of the defect. 
Newly formed bone was noted adjacent to the HA material 
(Figure 2A and B). Immunohistochemical staining against 
osteocalcin showed layers of osteoblasts depositing bone 
directly on the implant surfaces (Figure 2C).
At the end of the observation period, 6 months after 
implantation, the cells on the surface of the newly formed bone 
had the appearance of bone-lining cells. Fibrous encapsulation 
of the granules was not noted at any time and osteocytes were 
Figure 1 Frontal reconstruction of conventional computed tomography of the left 
tibia 6 months after creation of the defect. Bulky scar tissue was observed at the 
outer side of the defect. The defect cavity was filled with fibrous connective tissue 
(A). Histological section of the defect in the left tibia 6 months after creation of the 
defect (HE, original magnification 25×): There is no bony ingrowth into the defect. 
The defect itself is empty because the loose-fitting interconnecting tissue washed out 
during histological preparation. Hyaline cartilage can be seen on the right side (B). 
Histological section 6 weeks after implantation of the bone substitute material (HE, 
original magnification 100×): The implant is completely embedded into new bone. 
At the surface of the biomaterial, multiple darkly stained giant cells are detectable, 
marked  by  arrowheads  (C).  Histological  section  6  weeks  after  implantation 
(TRAP  staining,  original  magnification  200×): Arrowheads  indicate TRAP-positive 
multinucleated cells adjacent to the biomaterial at the interface (D).
Abbreviations:  HE,  hematoxylin  and  eosin;  HC,  hyaline  cartilage;  NFB,  newly 
formed  bone;  BGS,  bone  graft  substitute;  SCT,  soft  connective  tissue;  TRAP, 
tartrate-resistant acid phosphatase.
Figure 2 Histological section 12 weeks after implantation (HE, original magnification 
25×): ROI is marked by a dotted line. Bony ingrowth occurs from the margins of 
the defect, especially from the periost to the center of the defect (A). Detail of 
Figure 1A: The fractions of tissue are marked (B). Histological section 26 weeks after 
implantation (osteocalcin staining, 200×): Osteoblast activity along the biomaterial 
and fibrous tissue is visualized (arrowheads). Cement lines within the newly formed 
bone also stain positively for osteocalcin (C). Histological section 26 weeks after 
implantation  (TRAP  staining,  original  magnification  100×):  The  granules  of  the 
biomaterial are mostly surrounded by new bone formation, but in contrast to fibrous 
tissue  osteoclasts  are  still  detectable  (marked  by  arrowheads)  (D).  Histological 
section 26 weeks after implantation (HE, original magnification 100×): After a half-
year, cellular activity is still apparent at the interface between bone and biomaterial, 
particularly near the newly formed blood vessels (E).
Abbreviations: HE, hematoxylin and eosin; CD, center of the defect; NFB, newly 
formed  bone;  BGS,  bone  graft  substitute;  ROI,  region  of  interest;  SCT,  soft 
connective tissue; BV, blood vessel; TRAP, tartrate-resistant acid phosphatase.
found in close proximity to the surfaces of the Nanobone® 
implant. The surfaces of the implanted material were entirely 
covered with bone and the granules of Nanobone® were fully 
integrated into newly formed bone. The majority of surfaces 
were populated with cuboidal darkly stained cells, indicating 
active osteoblasts. The TRAP-positive multinucleated cells 
were also observed after 26 weeks within the new bone and in 
large numbers adjacent to the granules, indicating continuous 
remodeling (Figure 2D). Neovascularization was also evident 
within the pores at this time point (Figure 2E).
Histomorphometric analysis established that the majority 
of bone ingrowth occurred within the first 6 weeks and was 
terminated within 3 months. After 6 weeks 22% of the ROI was 
filled with bone, and after 3 months this proportion had increased 
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to 36%. This increase was statistically significant. Within the 
following 3 months, there was no further increase of bone 
ingrowth. After 6 months the volume fraction of bone was found 
to be approximately 30%. This difference was not statistically 
significant. The proportions of bone, bone grafting substitute, 
and connective soft tissue remained constant (Figure 3).
Micro-CT measurement was limited by the fact that the 
bone substitute material had a very similar X-ray adsorption 
to bone. Therefore, bone and bone substitute material could 
not be differentiated and were both set in relation to the 
unfilled space. Similar to the histomorphometric findings, 
a continuous decrease of soft tissue and a significant increase 
of radiopaque material with a bone-like appearance could be 
detected within the first 12 weeks. This bone-like material 
accounted for 55% of the defect volume after 6 weeks and 
increased to 73% and 78% after 3 months and 6 months, 
respectively (Figure 4).
Radiographic evaluation of the right tibiae filled with the 
bone substitute showed an increasing level of radiopacity 
both in standard radiographs and in conventional CT scans. 
In particular, the latter showed the defect area being filled 
with a high density material following 6, 12, and 26 weeks 
(Figure 4A–C).
Discussion
The ideal artificial bone substitute requires good biocompat-
ibility without inflammation or toxicity, sufficient mechani-
cal strength, strong bonding to the host bone, and active 
osteoconductivity to support bone ingrowth into the graft. 
Ultimately, the material would be replaced by or incorporated 
into host bone.21,22
In the present study we investigated the performance of 
a nanocrystalline hydroxyapatite (Nanobone®) embedded 
in a porous silica matrix with high porosity and surface 
area as a bone graft substitute. Application of Nanobone® 
to a weight-bearing defect of a large animal model has not 
previously been reported. The control defect showed no 
signs of a spontaneous bony healing or ingrowth. No signs 
of overloading were seen nor expected since the parameters 
of axial loading are well known.23 The high-loading capac-
ity of this model can be attributed to the high stiffness of 
the cortical and trabecular bone in sheep. No deformity or 
fracture was seen during the study period. The soft tissue 
healing process was uncomplicated in both the grafted and 
ungrafted tibiae.
During the entire 26-week period of this study, new 
bone was formed within the grafted defect with continuous 
osteoclastic and osteoblastic activity, indicating active bone 
remodeling. Both the high porosity and the pore size of the 
bone graft substitute appear to facilitate rapid ingrowth 
without intervening fibrous tissue. Previous experiments with 
rats showed that the matrix of Nanobone® was eliminated 
within a few days.12,24,25 Likewise, traces of matrix could not 
be detected histologically in the present sheep model after 
the initial study period of 6 weeks. Bone formation occurred 
Figure 3 Summary of the histomorphometric data: There is significant increase of 
the bone area within the first 3 months, while the fraction of the biomaterial remains 
unaffected over time. 
Notes: The fraction of the soft connective tissue shows a marked decrease within 
the first 12 weeks. Mean value ± standard error of the mean; analysis of variance; 
*P , 0.05 vs 6 weeks.
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Figure 4 Analysis of the micro-CT data: A decrease of the bone cavity with the 
simultaneous increase of radiopaque material is significant within the first 3 months, 
while the size of the cavity is diminishing. Conventional CT images at 6 (A), 12 (B), 
and 26 (C) weeks after the procedure and implantation of the biomaterial confirm 
these findings. 
Notes: Mean value ± standard error of the mean; analysis of variance; *P , 0.05 vs 
6 weeks.
Abbreviation: CT, computed tomography.
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starting from the defect margins and followed a centripetal 
direction to the center of the defect. This observation 
  corresponds to the reported deposition of bone from the 
defect walls toward the implant.26
At the bone–HA interface, osteoclastic activity could 
be observed throughout the entire 26-week experimental 
period. These findings indicate a high osteoconductivity of 
nanocrystalline HA. Furthermore, the presence of silicate 
ions appears to promote the process of bone formation and 
remodeling at the bone–HA interface.27–29
Histomorphometry showed the increase in bone volume 
inside the defect only within the first 12 weeks. During this 
time period, the matrix degraded10 and was sequentially 
replaced by connective tissue followed by capillary inva-
sion and differentiation of mesenchymal stem cells into 
  osteoblasts leading to bone formation.30 Multinucleated 
osteoclasts with ruffled borders colonized the HA surface. 
Degradation of the HA was not observed. Nanobone® is 
known to induce angiogenesis.31 This was confirmed in the 
present study by the presence of newly formed vessels within 
the grafted defect. Adequate blood supply is a prerequisite 
for cellular activity. This finding indicates equilibrium 
between bone resorption and bone formation during the 
remodeling process.
Both conventional CT and micro-CT data verified the 
histological and histomorphometric findings. An increase 
of radiopaque material within the grafted defect was seen 
over the first weeks. After 3 months a steady state had been 
reached. Since the HA was not degraded and remained within 
the defect, the increased radiopacity in the early time period 
is fully attributable to newly formed bone.
In the present study there was evidence of both osteoclastic 
and osteoblastic activity throughout the experimental 
duration. In contrast to what has been observed with 
other HA-based bone substitute materials,32 the rapid 
osseointegration of nanocrystalline HA seemed to prevent 
its complete degradation. At the end of the half-year 
experimental period, the Nanobone® particles were 
completely and firmly embedded within newly formed bone 
without a detectable fibrous interface and with no indication 
of an adverse host reaction to the material. These factors 
suggest that degradation of the nanocrystalline material at 
longer time periods seems unlikely and speak favorably 
for its clinical use.
Conclusion
This study demonstrated that Nanobone® is a biocompatible 
and osteoconductive material in a preclinical, loaded, 
large-animal model. This study further demonstrated that 
when implanted into a critical-size defect at the tibial head 
of sheep, the defect was rapidly filled with new bone that 
showed signs of vascularization within 3 months after 
implantation. The matrix binding the HA nanocrystals was 
quickly degraded, allowing rapid and complete integration 
of the nanocrystalline HA within the newly formed bone. 
These properties appear to be promising for the potential 
use as a bone substitute material in critical bone defects in 
clinical applications.
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